News About: Pharm. Affairs
Botulinum toxin market called red ocean starts second round
The domestic botulinum toxin market, which has become a red ocean, has started the second round.
Pharmaceutical companies which have struggled from cutthroat competition have secured differentiated competitiveness no...
Launch of Aspirin complex, Plavix A
‘Plavix A,’ a complex which combined an antiplatelet agent, ‘Plavix 75mg(generic name: clopidogrel),’ and aspirin(100mg) will be launched.
The launch of the Plavix/aspirin complex raised an expectation on convenience...
‘Baraclude’ falls, Lipitor and Viread form two-way strong trend
In the outpatient prescription market, ‘Lipitor(Pfizer)’ and ‘Viread(Gilead Sciences Korea)’ formed the 2-way strong trend.
The BMS Korea’s product which had exclusively led the market for the past years, ‘Baraclude...
Samsung applies Europe approval of ‘SB5,’ third biosimilar
On the 18th, Samsung Bioepis(CEO Han-seung Ko) announced application of the sales approval of the ‘Humira’ biosimilar, ‘SB5,’ to the EMA(European Medicines Agency).
SB5, the Samsung Bioepis’s third biosimilar product...
AstraZeneca encountered the most patent suits related to ‘Brilinta’
While a series of patent suits continues to be filed after the Patent-Linkage System is implemented, AstraZeneca was known to encounter the most number of patent challenges.
According to the analysis result of the M...
“Blind spots of insurance benefits on hepatitis C therapies, Sovaldi & Harvoni, will be resolved”
The hepatitis C treatment, ‘Harvoni(ledipasvir+sofosbuvir),’ will also be applied for the health insurance benefit even if the Dak-Sun combination therapy cannot be used.
Side effects which has been indicated as blin...
‘Xarelto’ registered for prioritized sales right as generic
The novel oral anticoagulant(NOAC), rivaroxaban(product name: Xarelto, Bayer)’ was registered in the list of pharmaceutical products with prioritized sales product approval for the 41th times.
SK Chemicals which suc...
Celltrion’s biosimilar ‘Remsima’ cruising European market
The world’s first biosimilar antibody developed by Celltrion, Remsima, has exceeded 70% in the European market share.
According to Celltrion, the Remsima’s market share growth rate in the last 1st quarter’s entire in...
Parecoxib concerning safety failed to come back again in 10 years
The Pfizer’s anti-inflammatory drug, ‘parecoxib(product name: dynastat),’ tried to enter the prescription market against its safety and efficacy issues again in 10 years, but finally failed.
The COX-2 inhibitor anti-...
‘Communication’ between Swiss President and domestic pharmaceutical industry
The pharmaceutical industry will have a meeting with the President of the Swiss Confederation, Johann Schneider-Ammann.
According to the industry, President Johann Schneider-Ammann will exchange opinions about the he...
